An Open-Label Study to Evaluate the Transition of Patients with Chronic Plaque Psoriasis from Cyclosporine to Alefacept

April 2007 | Volume 6 | Issue 4 | Original Article | 424 | Copyright © April 2007

Melissa A. Magliocco MD, Ann Marie Lozano RN BSN CCRC, Claudia Van Saders RN CCRC, Kristine W. Schuler MS, Alice B. Gottlieb MD PhD

Eleven patients with well-controlled psoriasis on cyclosporine (Physician’s Global Assessment [PGA] of “mild” or better) participated in an open-label study that evaluated a strategy for transition to alefacept. Using this transition strategy, 7 of 11 patients (64%) maintained PGA scores. Quality of life improved or was maintained in all patients. Adverse events and reductions in CD4+ T cell counts were consistent with those seen during alefacept monotherapy.